Indivior PLC (LON:INDV – Get Free Report)’s share price traded down 17% during trading on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 720.60 ($9.10). 2,904,792 shares were traded during mid-day trading, an increase of 294% from the average session volume of 737,710 shares. The stock had previously closed at GBX 868 ($10.97).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 1,800 ($22.74) target price on shares of Indivior in a research note on Tuesday, December 17th.
View Our Latest Stock Report on INDV
Indivior Price Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- 3 Small Caps With Big Return Potential
- DuPont’s Electronics Spinoff: The Start of Something Big
- Canadian Penny Stocks: Can They Make You Rich?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.